Medscape and ACC Centers of Excellence
The ACC has collaborated with Medscape to create two Centers of Excellence on the topics of Cardiovascular Risk Reduction and Heart Failure. This collaboration will expand the reach of expert information, including best practices in CV medicine, to improve patient care.
August 22, 2023
Upping the Pace in Acute Decompensated Heart Failure Therapy
April S. Stempien-Otero, MD, FACC
I'm here today to talk to you about new approaches in acute decompensated heart failure (ADHF) treatment.
August 1, 2023
Key Steps to Optimizing GDMT in Heart Failure
Biykem Bozkurt, MD, PhD, FACC
Today, we're discussing tips for optimizing guideline-directed medical therapy (GDMT) in heart failure.
July 17, 2023
Best Practices for Starting SGLT2 Inhibitors in HFpEF Treatment
Matthew C. Konerman, MD; Sarah K. Adie, PharmD
Today we are going to focus on a review of evidence supporting the use of SGLT2 inhibitors in HFpEF.
July 14, 2023
Measuring Atherogenic Lipids: Does One Equation Rise Above?
Pam R. Taub, MD, FACC; Seth Shay Martin, MD, MHS, FACC
We're going to talk today about the best way to measure atherogenic lipids.
May 16, 2023
Complementary and Alternative Medicines in HF: Key Takeaways From the AHA Statement
Marty Tam, MD, FACC; Christopher A. Giuliano, PharmD, MPH
The recently released scientific statement on complementary and alternative medicines (CAM) in the management of patients with heart failure (HF) from the American Heart Association (AHA) provides a much-needed evidence-based review of the role of CAM for patients with HF — including potential areas of harm.
May 12, 2023
Targeted Strategies in Lipid-Lowering Therapy: Where Do We Stand Now?
Seth J. Baum, MD, FACC, FAHA, FNLA, FASPC; Matthew J. Budoff, MD; Jay H. Shubrook, DO, FAAFP, FACOFP
I'm very happy to be here today to discuss clinical research in lipid-lowering therapies and lipoprotein-lowering therapies with my colleagues.
April 12, 2023
Practical Tips for Heart Failure Prevention
Payal Kohli, MD, FACC
Today we're discussing heart failure prevention strategies: what you can do and how you can educate your patients.
January 5, 2023
What About Lp(a)? To Test or Not to Test and the Current Treatment Landscape
Seth J. Baum, MD, FACC, FACPM, FAHA, FNLA, FASPC; Matthew J. Budoff, MD
Lp(a) is getting a large amount of attention lately. It's in a number of clinical trials, phase 3 and phase 2 clinical trials.
December 8, 2022
CRT in HFrEF Management: Updates Plus 'What's Next?'
Eugene S. Chung, MD, FACC, FHSFA; Ankit K. Bhatia, MD, FACC
It's a pleasure to talk a little bit about cardiac resynchronization therapy (CRT).
October 11, 2022
Are Heart Transplantation Outcomes Worse After the New OPTN Policy?
Alyssa Chang, MD; Monica M. Colvin, MD, MS
In 2016, the Organ Procurement and Transplantation Network (OPTN), which is administered by the United Network for Organ Sharing (UNOS), approved a new heart allocation policy that went into effect October 18, 2018.
October 3, 2022
The State of the Art in NAFLD/NASH Identification and Management
Seth J. Baum, MD, FACC, FAHA, FNLA, FASPC; Jay H. Shubrook, DO, FAAFP, FACOFP
Highly Anticipated Guidance: Practice Recommendations and Clinical Care Pathway
September 7, 2022
Stepping Up To Achieve Health Equity in Heart Failure
Alanna A. Morris, MD, MSc, FACC, FAHA, FHFSA; Khadijah Breathett, MD, MS, FACC, FAHA, FHFSA
We know the burden of heart failure is on the rise. It's well described as the leading cause of hospitalization in older adults over the age of 65 years.
August 1, 2022
What's New on the Lipid Management Landscape? The Experts Compare Notes
Pam R. Taub, MD, FACC, FASPC; Steven E. Nissen, MD, MACC
Eye-Opening Outcomes: Clinical Trial Results and Practice Recommendations
June 22, 2022
SGLT2 Inhibitors vs GLP-1 Agonists: Go It Alone or Join Forces? A Cardiologist and an Endocrinologist Weigh In
Matthew J. Budoff, MD; Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE
In this video interview, Drs. Handelsman and Budoff discuss the whole issue of the new medications for diabetes.
June 13, 2022
Heart Failure With Reduced Ejection Fraction: Advances in Management
Javed Butler, MD, MPH, MBA; Biykem Bozkurt, MD, PhD; Alanna A. Morris, MD, MSc
Along with me to discuss advances in management of patients with heart failure with reduced ejection fraction (HFrEF) are two of my respected colleagues and friends.
May 9, 2022
Recurrent Possible Cardiac Chest Pain and Mild Shortness of Breath in a 62-Year-Old Woman | Clinical Case
Matthew J. Budoff, MD
A 62-year-old Hispanic woman with possible cardiac chest pain and mild shortness of breath presents to a cardiologist as a new patient.
May 5, 2022
Hands On For Heart Failure: New Considerations For Cardiac Rehab
Daniel E. Forman, MD; Gordon R. Reeves, MD, MPT
To introduce this topic, I want to emphasize that cardiac rehabilitation, overall, is a multifaceted program that provides patient education and healthy lifestyle modifications that include both diet and physical activity.
March 28, 2022
Heart Failure With Preserved Ejection Fraction: New Treatments Provide 'Hope'
Clyde W. Yancy, MD, MSc; Ravi B. Patel, MD, MSc
We have the benefit now of a new universal definition that helps us understand who has heart failure and who doesn't.
March 15, 2022
Is Diabetes a Cardiovascular Risk Equivalent?
Jay H. Shubrook, DO, FAAFP, FACOFP; Mark L. Villalon, MD, FACC
Today's topic is one that I think we've all thought about and quite often quote. Is diabetes a cardiovascular risk equivalent?
January 7, 2022
Heart Failure Imaging: Where Are We Now?
Guilherme Marmontel Nasi, MD, Frederick L. Ruberg, MD, Monica Ahluwalia, MD
Approximately 6.2 million people in the United States had heart failure (HF) between 2013 and 2016, and prevalence of the condition continues to increase over time as the population ages.
December 1, 2021
Beyond Bone Health: Does Vitamin D Have a Role in Cancer, CVD, and COVID?
Pam R. Taub, MD, FACC, FASPC; JoAnn E. Manson, MD, DrPH, MACP; Michael F. Holick, MD, PhD
Hi. I'm Pam Taub. I'm a cardiologist and professor of medicine at UC San Diego.
November 2, 2021
Peripartum Cardiomyopathy Management: 5 Things to Know
Deirdre J Mattina, MD
The incidence of adverse pregnancy outcomes, particularly peripartum cardiomyopathy (PPCM), is on the rise in the United States.
October 18, 2021
Optimal Use of SGLT2 Inhibitors and GLP-1 Agonists: 5 Things to Know
Matthew J. Budoff, MD
For the first time in any trial of hypoglycemic therapy, the EMPA-REG OUTCOME study demonstrated a significant reduction in major adverse cardiovascular events (MACE).
October 5, 2021
Hypertrophic Cardiomyopathy: Do New Markers Enhance Risk-Stratification Models?
Tom Kai Ming Wang, MBChB, MD; Milind Desai, MD, MBA
Hypertrophic cardiomyopathy (HCM) is the most common form of hereditary heart disease, affecting 1 in 200-500 people.
August 25, 2021
Improving Cardiometabolic Health in the COVID-19 Era
Jay H. Shubrook, DO, FAAFP, FACOFP
Hi. I'm Jay Shubrook, a family physician, professor at Touro University of California, and a primary care diabetologist. I'm delighted to be here today to give a COVID update as it relates to cardiometabolic health.
July 26, 2021
Cancer Therapy and Myocardial Dysfunction: 5 Things to Know
Douglas J. Leedy, MD; Richard K. Cheng, MD, MSc; Sofia Carolina Masri, MD; Suma H. Konety, MD
In the United States, there are an estimated 17 million cancer survivors, a number projected to increase to 26 million by 2040.
June 30, 2021
2018 AHA/ACC Multisociety Cholesterol Guideline vs 2019 ESC/EAS Dyslipidemia Guidelines: 5 Things to Know
Andi Shahu, MD, MHS; David I. Feldman, MD, MPH; Erin D. Michos, MD, MHS, FACC, FAHA, FASE
Here are five notable similarities and differences between the AHA/ACC and ESC/EAS guidelines.
May 24, 2021
Cardiologists Should Be More Involved in Treating NAFLD/NASH
Seth J. Baum, MD, FACC, FAHA, FNLA, FASPC; Jay H. Shubrook, DO, FAAFP FACOFP
We know that NAFLD and its extension into NASH are significant contributors to disease and, at least in primary care, might be the most common cause of cryptogenic cirrhosis.
May 11, 2021
Tips for Navigating Prior Authorization and Out-of-Pocket Costs for HFrEF Medications
Larry A. Allen, MD, MHS; Sarah J. Sarni, BSN, BA
As clinicians, we know the importance of promptly initiating treatment for our patients with heart failure with reduced ejection fraction (HFrEF) to improve survival, rehospitalization, and medication adherence.
April 21, 2021
An Expert's Guide to Managing Familial Hypercholesterolemia
Seth J. Baum, MD, FACC, FAHA, FNLA, FASPC
One of the most important things to know about HeFH is that it's actually quite common, occurring in approximately 1 in every 200-250 people.
April 14, 2021
Do GLP-1 Agonists and SGLT2 Inhibitors Have a Role in HF Treatment?
Neelam Upadhyaya, MD; Ajay D. Rao, MD, MMSc
The management of patients with heart failure (HF) has taken an interesting and exciting turn thanks to studies demonstrating the positive effects and growing utilization of newer glucose-lowering therapies for reduction of HF outcomes — namely glucagon-like peptide 1 (GLP-1) agonists and oral sodium glucose cotransport 2 (SGLT2) inhibitors.
January 27, 2021
Antiplatelet Therapy: Where Do We Stand Now?
Sripal Bangalore, MD, MHA; Usman Baber, MD, MS
Welcome to this session, "Antiplatelet Therapy: Where Do We Stand Now?" This is Sripal Bangalore, interventional cardiologist and professor of medicine at New York University School of Medicine.
January 13, 2021
Does the Ketogenic Diet Benefit Patients With Heart Failure?
Kim L. Ho, BSc; John R. Ussher, PhD; Gary D. Lopaschuk, PhD
The ketogenic ("keto") diet, originally developed in the 1920s as an alternative treatment for pediatric epilepsy, remains a therapeutic strategy for a variety of conditions, including neurodegenerative diseases, diabetes, nonalcoholic fatty liver disease, cancer, and, most notably, weight loss.
November 23, 2020
CAC Scores, Lp(a), CRP: CV Screening in Real Life -- Who Really Needs It?
Seth J. Baum, MD, FACC, FACPM, FAHA, FNLA, FASPC; Matthew J. Budoff, MD
New American College of Cardiology/American Heart Association guidelines came out in 2018. They more strongly advocated for screening and recommended generally lower lipid targets than 2013.
November 10, 2020
Remote Monitoring Systems in Heart Failure: What's the Current Status?
Mary E. McClain, MSN; Katie M. Murphy, MBBCh, BAO; Brian W. Hardaway, MD
Hospitalization for heart failure (HF) marks a pivotal event in the disease course of our patients, one that carries a 1-year mortality rate of 25%.
October 7, 2020
Heart Failure With Preserved Ejection Fraction Management: 5 Things to Know
Daniel N. Silverman MD; Sheldon E. Litwin, MD; Ryan J. Tedford, MD
Patients with heart failure with preserved ejection fraction (HFpEF) represent approximately 50% of all HF cases.
September 10, 2020
Tips for Handling Polypharmacy and Medication Nonadherence in Patients With Heart Failure
Lynne M. Sylvia, PharmD; Robert L. Page II, PharmD, MSPH
Clinicians managing patients with heart failure (HF) won't be surprised that these patients take almost seven prescription medications per day, totaling around 10 doses a day.
August 28, 2020
What Do ISCHEMIA and CIAO Tell Us About CVD?
Pam R. Taub, MD, FACC, FASPC; Harmony R. Reynolds, MD
This interview will discuss the CIAO and ISCHEMIA trials.
August 6, 2020
Sodium Restriction in Heart Failure: What We Do and Don't Know
Author: Eloisa Colin-Ramirez, PhD; Justin Ezekowitz, MBBCh, MSc
This article offers an overview of what physicians know and still need to learn about sodium restriction and clinical outcomes of patients with HF over the long term.
July 16, 2020
SGLT2 Inhibitors Beyond Diabetes: A Team Effort in CVD and Renal Disease
Matthew J. Budoff, MD; Jay H. Shubrook, DO
This is a discussion about sodium-glucose cotransporter 2 (SGLT2) inhibitors and where they fit in cardiology versus primary care practice today.
June 23, 2020
Novel Lipid Therapies: 5 Things to Know
Alan P. Jacobsen, MB, BCh, BAO; Eamon Y. Duffy, MD, MBA; Seth S. Martin, MD, MHS
This article offers physicians five things to know about novel pharmacotherapies targeting low-density lipoprotein (LDL), lipoprotein a, and triglycerides (TG) to help prevent patients' risk of atherosclerotic cardiovascular disease (ASCVD).
May 28, 2020
Heart Failure Prevention Post-Myocardial Infarction:5 Things to Know
Musa A. Sharkawi, MBBCh; Ajar Kochar, MD, MHS
This article offers physicians five things to know about the prevention and management of HF in patients after MI.
January 28, 2020
Effecting Dietary Modifications in Patients: 5 Things to Know
Amit Khera, MD, MSc, FACC; Susan G. Rodder, MS, RDN, LD
This article offers physicians five things to know about effecting successful dietary modifications in patients.
December 11, 2019
2019 CVD Primary Prevention Guideline: 5 Things to Know
Erin D. Michos, MD, MHS; Andi Shahu, MD, MHS
To enhance patient care and lower the prevalence and incidence of CVD, the American College of Cardiology (ACC) and American Heart Association (AHA) published concise guideline recommendations for the primary prevention of CVD.
November 15, 2019
The Role of Non-statin Therapy for Secondary Prevention of ASCVD: Clinical Case
Salim S. Virani, MD, PhD, FACC; Xiaoming Jia, MD; Jay H. Shubrook, DO
Case Presentation: A 64-year-old woman sees her cardiologist for a routine follow-up visit after a second myocardial infarction (MI).
November 1, 2019
2018 Updated AHA/ACC Multisociety Cholesterol Guideline: 5 Things to Know
Neil J. Stone, MD, FACC; Scott M. Grundy MD, PhD
The updated 2018 AHA/ACC Multisociety Cholesterol Guideline further refined the secondary prevention category and expanded the scope of primary prevention to include all age groups. This piece offers five things to know about the 2018 AHA/ACC guideline.
October 16, 2019
Aspirin Recs Go Topsy-Turvy in New Guidelines: Now What?
Michael D. Miedema, MD, MPH; J. William McEvoy, MB BCh, MHS
ACC/AHA primary prevention guideline authors Bill McEvoy and Mike Miedema discuss practical aspects of aspirin use after its recent downgrade based on studies showing little to no benefit.
June 19, 2019
Cardiologists Must 'Get Up To Speed' on Treating Diabetes
Cardiologists currently see more patients with diabetes than do endocrinologists, according to a study presented at the 2019 Endocrine Society Annual Meeting in New Orleans. Despite these figures, many cardiovascular (CV) specialists report being poorly equipped to address diabetes with novel agents.
April 11, 2019
CVD Primary Prevention Guideline Puts Patients Center Stage
Salim S. Virani, MD, PhD, FACC; Donna K. Arnett, MSPH, PhD; Erin D. Michos, MD, MHS
Watch Writing Committee Members discuss the new Guideline for Primary Prevention of Cardiovascular Disease.
February 25, 2019
Medscape/ACC Survey Looks at CV Risk Factor Management
The Survey Sheds Light on How Cardiologists Currently Address Diet and Lifestyle, Hypertension, and Type 2 Diabetes in Their Patients.
Keywords: Heart Failure, Risk Reduction Behavior, Risk Factors, Primary Prevention
< Back to Listings